Loading...
•
Mar 31, 2023
Xencor Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Xencor reported a net loss of $60.8 million, or $(1.02) per share, for the first quarter ended March 31, 2023. Revenues were $19.0 million, compared to $85.5 million for the same period in 2022. Cash, cash equivalents, receivables and marketable debt securities totaled $568.2 million as of March 31, 2023.
Xencor plans to advance two new programs into clinical development this year: XmAb662 and XmAb541.
Updated results from the Phase 1a study of XmAb564 will be presented at EULAR Congress.
Xencor has opened an expansion portion in the Phase 1 study of XmAb104 to evaluate it in combination with ipilimumab.
Nancy Valente, M.D., was appointed as Xencor’s Executive Vice President, Chief Development Officer.
Forward Guidance
Xencor expects to have cash to fund research and development programs and operations through the end of 2025. The Company expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...